Table 1

Impact of NAI therapy starting at 24 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) WT virusa

Regimen% mortality on day 12 p.i. (n = 8)Mean % wt loss ± SD on day 5 p.i. (n = 11–12)Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4)
Uninfected/untreated0***−3.5 ± 0.7***Nd
Untreated-infected7515.6 ± 1.52.85 × 105 ± 0.1 × 105
Oseltamivir 5 × 1 mg/kg0***7.2 ± 1.2**1.3 × 102 ± 0.65 × 102***
Peramivir 1 × 90 mg/kg0***−2.5 ± 0.9***4 × 101 ± 1 × 101***
Peramivir 5 × 45 mg/kg0***−2.6 ± 1.1***0.66 × 101 ± 0.11 × 101***
  • a **, P < 0.01; ***, P < 0.001 (versus the untreated group). Statistical significance was determined by using Kaplan-Meier analysis for mortality and a one-way ANOVA test for weight loss and lung viral titers. Nd, not determined. The viral inoculum was 6.9 × 103 PFU.